A Phase III Multicentre, Parallel-group, Randomized, Placebo-controlled, Double-blind Clinical Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Chronic Urticaria

Trial Profile

A Phase III Multicentre, Parallel-group, Randomized, Placebo-controlled, Double-blind Clinical Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Chronic Urticaria

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Oct 2017

At a glance

  • Drugs Desloratadine (Primary)
  • Indications Urticaria
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 18 May 2016 Primary endpoint has been met. (Change From Baseline in the Sum Score of Pruritus/Itch and Rash Assessed by Investigator at Week 2), as per results presented at the 112th International Conference of the American Thoracic Society.
    • 18 May 2016 Results presented at the 112th International Conference of the American Thoracic Society
    • 27 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top